APTAH
Live / Applied — Fifth extension granted (statement of use) (as of 07 Nov 2025)
What this means for you
Not registered yet, but its 23 Sept 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97041301
- Mark type
- Stylized text
- Filed
- 23 Sept 2021
- Published for opposition
- 29 Nov 2022
- Attorney of record
- Alyssa M. Worsham
Goods and services
- Class 001 — Chemicals: Biomolecules in the nature of gene therapy products, namely, genetically engineered stem cells in the nature of synthetic cDNAs for controlling gene expression for medical and scientific research
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the configuration, modulation and correction of RNA transcript splicing, capping and tailing for the treatment of genetic diseases; pharmaceutical preparations for the configuration, modulation and correction of RNA for the treatment of genetic diseases; pharmaceutical preparations for restoring and reprograming RNA-protein interactions for the treatment of genetic diseases; pharmaceutical preparations for the treatment of genetic diseases associated with gene dysregulation, inhibition or suppression of gene expression; pharmaceutical preparations for the treatment of genetic diseases; gene therapy products, namely, molecules in the nature of genetically engineered tissues for controlling gene expression; medical molecular diagnostic tests for testing bodily fluid for the detection of genetic diseases; medical diagnostic tests for the detection of neurodegenerative, oncological and infectious diseases
- Class 042 — Scientific and technological services: Research and development of pharmaceuticals, namely, therapies for the configuration, modulation and correction of RNA transcript splicing, capping and tailing; scientific research and development of therapies in the fields of biotechnology, genetic medicine, gene therapy, DNA, RNA, molecules and proteins; pharmaceutical products design and development in the field of biomolecules for medical and scientific use, and medical treatment; pharmaceutical drug design and development featuring biomolecules
Owner
- Aptah Bio Inc., San Carlos, CA, US
- Aptah Bio Inc., San Carlos, CA, US
Prosecution history
- 13 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 08 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Nov 2025 — SOU EXTENSION 5 GRANTED
- 30 Jun 2025 — SOU EXTENSION 5 FILED
- 30 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Jan 2025 — SOU EXTENSION 4 GRANTED
- 17 Jan 2025 — SOU EXTENSION 4 FILED
- 17 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jul 2024 — SOU EXTENSION 3 GRANTED
- 08 Jul 2024 — SOU EXTENSION 3 FILED
- 08 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 26 Jan 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jan 2024 — SOU EXTENSION 2 GRANTED